With Positive Phase II Data on HCV Drug, Santaris Aims for Another Clinical Trial by the Summer | GenomeWeb

Having just released phase IIa data demonstrating the antiviral activity of its microRNA-targeting hepatitis C treatment miravirsen, Santaris Pharma is preparing to begin within a few months another phase II study that will examine the drug in combination with direct-acting antiviral agents, a company official said.

“Miravirsen is certainly doing what it says on the bottle … [demonstrating] a high barrier to resistance [with] good saturation and distribution within the liver,” Santaris CMO Michael Hodges told Gene Silencing News this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.